Screener
Roivant Sciences ROIV Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Efficiency | ||||||
| Asset turnover | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Liquidity | ||||||
| Current ratio | 16.7×-23.8× | 18.4×-15.1× | 30.7×-7.2× | 33.7×+23.3× | 40.5×+12.6× | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Per Share | ||||||
| Book value per share | $5.87-8.1% | $6.52+1.0% | $6.13-14.7% | $6.41-8.6% | $6.39-8.1% | |
| Valuation | ||||||
| Market capitalization | $24.71B+124% | $19.82B+175% | $15.09B+75.3% | $10.33B+21.7% | $7.84B+0.9% | |
| Price / sales | 3,280.8×+2,739× | 2,400.1×+2,152× | 1,133.9×+852× | 508.2×+279× | 337.7×+123× | |
| Price / book | 5.8×+3.3× | 4.4×+2.8× | 3.5×+1.9× | 2.4×+0.7× | 1.8×+0.4× |
FAQ
- Where do Roivant Sciences's ratios come from?
- Every ratio is computed from Roivant Sciences's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
